Amalgamated Bank Inhibrx, Inc. Transaction History

Amalgamated Bank

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$32.76 - $39.56 $100,704 - $121,607	-3,074 Reduced 72.33%	1,176 $41,000
Q4 2023 Feb 06, 2024	SELL	$14.5 - $38.0 $5,075 - $13,300	-350 Reduced 7.61%	4,250 $162,000
Q2 2023 Aug 11, 2023	SELL	$16.96 - $27.82 $67 - $111	-4 Reduced 0.09%	4,600 $119,000
Q1 2023 May 02, 2023	SELL	$18.45 - $27.14 $15,645 - $23,014	-848 Reduced 15.55%	4,604 $87,000
Q4 2022 Feb 10, 2023	BUY	$20.18 - $33.33 $16,850 - $27,830	835 Added 18.09%	5,452 $134,000
Q3 2022 Nov 09, 2022	BUY	$11.58 - $24.73 $822 - $1,755	71 Added 1.56%	4,617 $83,000
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $8 - $25	1 Added 0.02%	4,546 $52,000
Q1 2022 Jun 30, 2022	SELL	$19.89 - $43.18 $7,617 - $16,537	-383 Reduced 7.77%	4,545 $101,000
Q4 2021 Feb 15, 2022	BUY	$26.75 - $46.02 $131,824 - $226,786	4,928 New	4,928 $215,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $550M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.